A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Recruiting now · Phase 1/Phase 2
Conditions studied: Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
In brief
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Key facts
- Study ID
- NCT04370587
- Run by
- ImmVira Pharma Co. Ltd
- People needed
- 30
- Starts
- 2020-09-17
- Expected to finish
- 2027-01-10
- Last updated by the study team
- 2025-10-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Alfred — Melbourne, Australia (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States (enrolling)
- Mary Crowley Cancer Research — Dallas, Texas, United States (enrolling)
- Virginia Cancer Specialists — Fairfax, Virginia, United States (enrolling)
- Southern Oncology — Bedford Park, Australia (enrolling)
- Peninsula & South Eastern Haematology and Oncology Group — Frankston, Australia (enrolling)
- Banner MD Anderson Cancer Center — Gilbert, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.